97 related articles for article (PubMed ID: 1804864)
1. Pharmacokinetic comparison of flurbiprofen in end-stage renal disease subjects and subjects with normal renal function.
Cefali EA; Poynor WJ; Sica D; Cox S
J Clin Pharmacol; 1991 Sep; 31(9):808-14. PubMed ID: 1804864
[TBL] [Abstract][Full Text] [Related]
2. Influence of H2 receptor antagonists on the disposition of flurbiprofen enantiomers.
Small RE; Cox SR; Adams WJ
J Clin Pharmacol; 1990 Jul; 30(7):660-4. PubMed ID: 2391398
[TBL] [Abstract][Full Text] [Related]
3. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of aztreonam administered i.p. in continuous ambulatory peritoneal dialysis (CAPD) patients.
Nikolaidis P; Dombros N; Alexiou P; Balaskas E; Tourkantonis A
Perit Dial Int; 1989; 9(1):57-9. PubMed ID: 2488183
[TBL] [Abstract][Full Text] [Related]
5. Single-dose pharmacokinetics of cefpirome in patients receiving hemodialysis and in patients treated by continuous ambulatory peritoneal dialysis.
Veys N; Lameire N; Malerczyk V; Lehr KH; Rosenkranz B; Ringoir S
Clin Pharmacol Ther; 1993 Oct; 54(4):395-401. PubMed ID: 8222482
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of flurbiprofen and its enantiomers.
Davies NM
Clin Pharmacokinet; 1995 Feb; 28(2):100-14. PubMed ID: 7736686
[TBL] [Abstract][Full Text] [Related]
7. Comparison of plasma amino acid concentrations in end-stage renal disease patients on hemodialysis and peritoneal dialysis.
Kim DH; Yang DH; Hong SY
Korean J Intern Med; 1998 Feb; 13(1):33-40. PubMed ID: 9538629
[TBL] [Abstract][Full Text] [Related]
8. Clearance of iopamidol, a non-ionic contrast medium, by CAPD in patients with end-stage renal failure.
Donnelly PK; Burwell N; McBurney A; Ward JW; Walls J; Watkin EM
Br J Radiol; 1992 Dec; 65(780):1108-13. PubMed ID: 1286420
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure.
Asari A; Iles-Smith H; Chen YC; Naderer OJ; Johnson MA; Yuen GJ; Otto V; Dunn JA; Gokal R
Br J Clin Pharmacol; 2007 Dec; 64(6):738-44. PubMed ID: 17662093
[TBL] [Abstract][Full Text] [Related]
10. Effects of chronic renal failure on the pharmacokinetics of ruboxistaurin and its active metabolite 338522.
Wise S; Yuen E; Chan C; Poo YK; Teng L; Lau T; Voelker J
Clin Pharmacokinet; 2006; 45(3):297-303. PubMed ID: 16509761
[TBL] [Abstract][Full Text] [Related]
11. Single-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients.
El-Assal MI; Helmy SA
Biopharm Drug Dispos; 2014 Oct; 35(7):405-16. PubMed ID: 25044219
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.
MacPhee IA; Spreafico S; Bewick M; Davis C; Eastwood JB; Johnston A; Lee T; Holt DW
Kidney Int; 2000 Mar; 57(3):1164-8. PubMed ID: 10720968
[TBL] [Abstract][Full Text] [Related]
13. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.
Lee CR; Pieper JA; Frye RF; Hinderliter AL; Blaisdell JA; Goldstein JA
Eur J Clin Pharmacol; 2003 Apr; 58(12):791-4. PubMed ID: 12698304
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of icodextrin in peritoneal dialysis patients.
Moberly JB; Mujais S; Gehr T; Hamburger R; Sprague S; Kucharski A; Reynolds R; Ogrinc F; Martis L; Wolfson M
Kidney Int Suppl; 2002 Oct; (81):S23-33. PubMed ID: 12230479
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
[TBL] [Abstract][Full Text] [Related]
16. Stereoselective disposition of flurbiprofen in uraemic patients.
Knadler MP; Brater DC; Hall SD
Br J Clin Pharmacol; 1992 Apr; 33(4):377-83. PubMed ID: 1576066
[TBL] [Abstract][Full Text] [Related]
17. Alprazolam in end-stage renal disease: I. Pharmacokinetics.
Schmith VD; Piraino B; Smith RB; Kroboth PD
J Clin Pharmacol; 1991 Jun; 31(6):571-9. PubMed ID: 1880224
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of quinapril and its active metabolite quinaprilat during continuous ambulatory peritoneal dialysis.
Swartz RD; Starmann B; Horvath AM; Olson SC; Posvar EL
J Clin Pharmacol; 1990 Dec; 30(12):1136-41. PubMed ID: 2273086
[TBL] [Abstract][Full Text] [Related]
19. Plasma free amino acids and their metabolites in Taiwanese patients on hemodialysis and continuous ambulatory peritoneal dialysis.
Chuang CK; Lin SP; Chen HH; Chen YC; Wang TJ; Shieh WH; Wu CJ
Clin Chim Acta; 2006 Feb; 364(1-2):209-16. PubMed ID: 16087168
[TBL] [Abstract][Full Text] [Related]
20. Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis.
Shah GM; Winer RL; Krasny HC
Am J Kidney Dis; 1986 Jun; 7(6):507-10. PubMed ID: 3717158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
